PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.28%
Revenue growth under 50% of MRVL's 11.65%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.54%
Gross profit growth under 50% of MRVL's 10.19%. Michael Burry would be concerned about a severe competitive disadvantage.
10.98%
EBIT growth below 50% of MRVL's 25.75%. Michael Burry would suspect deeper competitive or cost structure issues.
10.98%
Operating income growth under 50% of MRVL's 25.75%. Michael Burry would be concerned about deeper cost or sales issues.
27.66%
Net income growth comparable to MRVL's 26.89%. Walter Schloss might see both following similar market or cost trajectories.
32.00%
EPS growth 1.25-1.5x MRVL's 25.00%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
28.00%
Diluted EPS growth above 1.5x MRVL's 14.29%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-1.93%
Share reduction while MRVL is at 3.06%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.28%
Reduced diluted shares while MRVL is at 4.10%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.79%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
86.17%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
308.00%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
7.93%
10Y revenue/share CAGR under 50% of MRVL's 271.49%. Michael Burry would suspect a lasting competitive disadvantage.
32.39%
5Y revenue/share CAGR under 50% of MRVL's 271.49%. Michael Burry would suspect a significant competitive gap or product weakness.
69.82%
3Y revenue/share CAGR under 50% of MRVL's 271.49%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
102.84%
10Y OCF/share CAGR under 50% of MRVL's 421.95%. Michael Burry would worry about a persistent underperformance in cash creation.
72.68%
Below 50% of MRVL's 421.95%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
172.49%
3Y OCF/share CAGR under 50% of MRVL's 421.95%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
158.75%
Net income/share CAGR at 50-75% of MRVL's 315.42%. Martin Whitman might question if the firm’s product or cost base lags behind.
36.06%
Below 50% of MRVL's 315.42%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
564.91%
3Y net income/share CAGR above 1.5x MRVL's 315.42%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
285.05%
Below 50% of MRVL's 859.66%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
58.13%
Below 50% of MRVL's 859.66%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.89%
Below 50% of MRVL's 859.66%. Michael Burry suspects a serious short-term disadvantage in building book value.
39.88%
Dividend/share CAGR of 39.88% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
5.99%
Dividend/share CAGR of 5.99% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-6.00%
Negative near-term dividend growth while MRVL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
1.81%
AR growth is negative/stable vs. MRVL's 16.45%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
5.53%
Inventory shrinking or stable vs. MRVL's 27.46%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
0.54%
Asset growth well under 50% of MRVL's 4.29%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.72%
BV/share growth above 1.5x MRVL's 1.89%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-51.52%
We’re deleveraging while MRVL stands at 32.31%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-6.03%
Our R&D shrinks while MRVL invests at 5.54%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.93%
We cut SG&A while MRVL invests at 10.58%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.